Mary Wilson
Well-known member
Posted: 24 Feb 2023
Available at SSRN: https://ssrn.com/abstract=4366836 or http://dx.doi.org/10.2139/ssrn.4366836
Hugo D.G. van Willigen1 (MD), Elke Wynberg1,2# (MBBS MSc), Anouk Verveen3#, Maartje Dijkstra2,4 (MD PhD), Bas J. Verkaik4 (MD), Orlane J.A. Figaroa4 (MD), Marianne C. de Jong2, Annelou L.I.P. van der Veen4,6 Agata Makowska2, Nelleke Koedoot2, Pythia T Nieuwkerk3 (PhD), Anders Boyd2,6, Maria Prins2,4 (PhD), 7 Godelieve J. de Bree4 (MD PhD), Menno D. de Jong1 (MD PhD), Joost G. van den Aardweg5 (MD PhD), and the RECoVERED Study Group.
Abstract
Background: This longitudinal study evaluates the extent of impaired pulmonary function over time after SARS-CoV-2 infection across the full spectrum of COVID-19 severity.
Methods: Pulmonary function was measured by diffusing capacity for carbon monoxide (DLCO) at one, six, and twelve months after illness onset. Additionally, data on sociodemographics, clinical characteristics, symptoms, and health-related quality of life (HRQL) were collected. Pulmonary function and determinants were modelled over time using mixed-effect linear regression. Determinants of pulmonary impairment at 12 months since illness onset were identified using logistic regression.
Findings: Between May 2020 and December 2021, 301 of 349 participants underwent at least one pulmonary function test. After one year of follow-up, 25% of the participants had an impaired pulmonary function which translates in 11%, 22%, and 48% of the participants with mild, moderate and severe/critical COVID-19. Improvement in DLCO among the participants continued over the period across one, six and twelve months. Having more than three comorbidities (p<0·001) and initial severe/critical illness (p<0·001) were associated with slower improvement of pulmonary function over time, adjusted for age and sex. HRQL improved over time and was not different to those without impaired pulmonary function.
Interpretation: The prevalence of impaired pulmonary function after twelve months of follow-up, was still significant among those with initially moderate or severe/critical COVID-19. However, those who continued to have impaired pulmonary function after one year did not have impaired HRQL.
Download:
https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4366836
Available at SSRN: https://ssrn.com/abstract=4366836 or http://dx.doi.org/10.2139/ssrn.4366836
Hugo D.G. van Willigen1 (MD), Elke Wynberg1,2# (MBBS MSc), Anouk Verveen3#, Maartje Dijkstra2,4 (MD PhD), Bas J. Verkaik4 (MD), Orlane J.A. Figaroa4 (MD), Marianne C. de Jong2, Annelou L.I.P. van der Veen4,6 Agata Makowska2, Nelleke Koedoot2, Pythia T Nieuwkerk3 (PhD), Anders Boyd2,6, Maria Prins2,4 (PhD), 7 Godelieve J. de Bree4 (MD PhD), Menno D. de Jong1 (MD PhD), Joost G. van den Aardweg5 (MD PhD), and the RECoVERED Study Group.
Abstract
Background: This longitudinal study evaluates the extent of impaired pulmonary function over time after SARS-CoV-2 infection across the full spectrum of COVID-19 severity.
Methods: Pulmonary function was measured by diffusing capacity for carbon monoxide (DLCO) at one, six, and twelve months after illness onset. Additionally, data on sociodemographics, clinical characteristics, symptoms, and health-related quality of life (HRQL) were collected. Pulmonary function and determinants were modelled over time using mixed-effect linear regression. Determinants of pulmonary impairment at 12 months since illness onset were identified using logistic regression.
Findings: Between May 2020 and December 2021, 301 of 349 participants underwent at least one pulmonary function test. After one year of follow-up, 25% of the participants had an impaired pulmonary function which translates in 11%, 22%, and 48% of the participants with mild, moderate and severe/critical COVID-19. Improvement in DLCO among the participants continued over the period across one, six and twelve months. Having more than three comorbidities (p<0·001) and initial severe/critical illness (p<0·001) were associated with slower improvement of pulmonary function over time, adjusted for age and sex. HRQL improved over time and was not different to those without impaired pulmonary function.
Interpretation: The prevalence of impaired pulmonary function after twelve months of follow-up, was still significant among those with initially moderate or severe/critical COVID-19. However, those who continued to have impaired pulmonary function after one year did not have impaired HRQL.
Download:
https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4366836